Jul 25, 2017 • 7:00 AM EDT

Q2 2017 Quarterly Results

Quarter Ended Jun 30, 2017

142% increase in consolidated revenue to $60.8 million

150% increase in clinical genetic testing volume

Diluted EPS of ($0.07) per share and Adjusted Diluted EPS of $0.04 per share

Year-to-date cash flow from operations of $21.7 million

Company Profile

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.

Latest 10-K

View Latest 10-K

NeoGenomics, Inc.

NASDAQ: NEO

Market/Symbol

Price

Change

Volume

Day Range

52 week Range

IR Contact Information

Investor Relations Steven Jones
Executive Vice President & Chief Compliance Officer
T: (239) 325-2001
sjones@neogenomics.com

Transfer Agent Standard Registrar & Transfer Company
12528 South 1840 East
Draper, UT 84020
T: (801) 571-8844